XX% to Matt. Good with today with strong you margins. significantly be we excited joining you you, I’m second report for revenue quarter improved afternoon, gross sequential growth a as Thank us. and all thank and
including for Pantheris platform, which can the as of X,XXXth our XX%. small made of progress disease, of our expand Pantheris we’ve treatment During the the substantial case available SV mid-quarter with the on as believe Lumivascular much our clearance market by quarter, and FDA we vessel next-generation announcement U.S.
Hong the This of initiation third successful clinical the studies, Pantheris first international treatment our in our launch expansion, a education of of announced Earlier carried week we commercial the device progress into and launch Australia. image-guided this SV is signing Ocelot positive important quarter. for with our recently in patients programs also U.S. the and an Kong reported clinical momentum new distribution limited of the and We’ve in agreement CTO-crossing
these efforts, maintaining On happy the data, clinical beyond: continued initiatives our discussed compelling current We’ve business. underserved revenue XXXX per a made through with of site drive in against markets; key progress to benefits second, and sites past strong fifth, we demonstrating are significant as in first, in introducing PAD; rates our of fourth, market devices new driving high opportunity; sites third, five calls, growth expand to and areas current to strategies launching producing new utilization at addressable in we’ve report our the second Avinger’s scale fuel Lumivascular and lean and a operating platform; establishing foundation I’m all the quarter to growth. of these structure unique and
these progress over areas review of Let’s made each the past some specific of in months. the we’ve few
in quarter and XX% catheters, market in we we the and into resulting positive treatment realized the platform, second utilization, in U.S. strong the sites a XXXX. markets. our a year-ago by activity compared the first which This in strong in introduced increase increase sequential current the of in in growth increase and of generation quarter, at Pantheris was utilization XX% a of orders market increase of revenue adoption current to the driven next from second indication driving the quarter use quarter. revenue First, and In XX%
grew XX year-over-year total conducted increase To training Pantheris force quarter, hires our strength Pantheris platform, this the of ordering year. more additional and four for than the the expect our next-generation second since in strategic these with program capability, largest XX% years. investment sales to more sales experienced continue XX, than accounts of and in fuel half to the the overall months the second next-generation professionals in end force. case already growth of the growth at on throughout in the past sales launch. of our our we to an hired our our Based revenue bringing coverage of extensive first sales XXXX, to quarter expansion three make new them contribute six headcount We’ve We’ve
and of our this the high our accept sites with wider underserved we’ve We SV We universe on had sites approximately track user to our believe XX products. is previously, our resources our and Pantheris success the southeast sales in coverage launch areas to team XXXX. to successfully our this to year. professionals we’ve sales continued cases, second expansion our critical of in volume the and and initiative, strategically in by sales high of are new our of Pantheris well growth of to the growth in sales half new organization target the in execute force of make support geographic including second physicians. enabled continued new this achieve to is contribute rates By markets, of ramping centers Expanding launching Lumivascular areas limited southwest PAD. of We investment ability year-end a important technology adding launch increased available new in to where
revenue third to per addressable devices expand to Turning area, site new our our and market growth opportunity. launching
a The cases centers four XX our cases. completion We’re two variety cardiologist office-based settings, in week. this sites and U.S. full the surgeons swing U.S. first PAD, to and the two the interventional vascular labs around launch of initial performed hospitals successful Pantheris of with first including clinical two in initiative on opinion the in of recent last key Three in the country. and leaders place took treatment announcement of were SV cases
was of able vasculature. of wide ability three clarity in provided by extremely various the of Physicians and of feedback safety successfully lesions achieved in cutting onboard with I and impressed Early been first the the positive outcomes a range the regions those below treated for of personally challenging device far by imaging, the the imaging. and observe the knee, levels cases. the was including arteries of very a by users sites calcification of physicians number on has first these the in cases clinical commenting with to distal
of above SV physicians popliteal debulk occluded successfully and knee. Pantheris device, used versatility knee and the arteries artery lesions the also the highly vessels the Demonstrating behind and to challenging-to-treat the
While launch we’re by we’re process, results the in still early our in encouraged these initial early sites.
three Additional and process SV cases out to week. centers, the in rolling in we’re of sites are Pantheris ongoing additional this these
expect approximately and end We the running of program up have XX to launch sites August. in our by
our Following plan U.S. to treatment expand to these experience and Europe. we additional distribution broadly commercial facilities in centers, initial in the
allow larger available highly could that in address million a that smaller as knee, the larger or a SV much significant By onboard estimated we providing Avinger device of our portion procedures believe Pantheris to vessels, address those million below the atherectomy basis, it significantly with with by occurring XX% the luminal a sites, day-to-day market share as market. imaging. will $XXX already and of our user $XXX especially differentiated expand gain On safety a also to of the combines atherectomy enable to company access
to commercial broad for team in clinical launch building product any inventory code preparing support We’re with commercial necessary the by add Lumivascular providing clinical current and to accounts ordering sites, broad our the updates imaging to their to systems, Pantheris training Lightbox launch. SV working support console
fee the to revenue increasing be to case volume Pantheris expect a XXXX. and second We in half drive growth our creative of
next our CTO in product image guided Ocellaris, is pipeline up development our device. crossing Next generation
We continue the excellent Mark in in commercialization initial to case device anticipate of on this progress experience CE Europe half and second this for gaining and advanced make year.
use U.S. FDA Ocellaris arteries. the for anticipate the application initial this submitting XXX(k) a case experience, in with Following we of the peripheral
the according us This launch next into If we of new three hope to introductions Pantheris all next-gen of in market launch Ocellaris goes position give product platform year. U.S. XXXX, SV Pantheris to in robust Ocellaris in of plan, years launch launch of anticipated XXXX the U.S. a be in catheter will a three in and the to with XXXX. the the and
artery, For is which for Ocelot devices will of occlusion extension new PAD. the on be only space, blocked catheters, most challenging-to-treat those forms first available one of CTO-crossing CTO and PAD a of you new the family of our of the severe chronic completely or and market. Ocellaris product stands image-guided to a total
We imaging for believe as that OCT maneuverability. speeds a these range high-definition rpm as other to at to streamlined CTOs. of in a such to provide up the procedure as device This for result of precise leverage real-time, next-generation well greater a a more will ability is a easier and utility treat to improvements wider incorporates number X,XXX use tip steerable will and device physicians spin advances, and
and CTOs We the the arteries are treatment are peripheral new starting this of for of there. excited about in technology the platform application
to invasive technology the safety of our in primary the believe the also a this in We in and coronary are development precision programs to with and we we for medical the a plan the the this community, treatment arteries development coronary coronary arteries. to focus unmet work technology for in expect represent for see need transition XXXX. and peripheral one for specific surgery potential product critical devices. arteries our in Total this completed a the the been highly of blockages be we of Once apply great our R&D application CTOs arteries, deliver of Ocellaris need substantial coronary to R&D of bypass can with platform a image-guided has driver
publication support fourth good producing publication compelling delivery data April, primary progress data from announced and restenosis indication with XXX% of patency of this In clinical therapy. outcomes of freedom XX Lumivascular made of antirestenotic months. patients the rate atherectomy The a is with to XX% lesion also our outstanding was We’ve an platform. from target clinical study Pantheris we revascularization, outstanding prior on study for image-guided in strategic reporting our treated a initiative, the which reporting at
operator a from presentation Hospital in is the one transmission in CVC. trial, presentations principal In plus was who technology July, Chicago. five study the conference presented Schwindt’s Dr. featuring Munster XXXX CVC Lumivascular podium findings clinical Germany, Franziskus this at case at Dr. Schwindt of the live the Arne in St. from our
the and and May. our or taking and data in clinical NCVH community of is treatment In the four clinical data clinical clinical approach The support podium were key Cardiovascular in highlighted at New presentations of the to PAD our by building technologies annual opinion addition, is Horizons notice. leaders conference unique
We extremity Dr. ISR multicenter Pantheris Early Dwight recently positive are at our enrollment study in-site IDE very restenosis of patients in XXth Dishmon, trial, in an our CVC enrolled encouraging, clinical for interim patient first July. arteries. to results treating lower and evaluate interventional in announced designed presented or a the and study the results from in study, physician cardiologist in XX the in-stent investigator
or target achieved XX these six use physicians lesion XX% reduction therapy. was stenosis months. TLR than alone. or adjunctive the blockage in after Pantheris XX% patients, of the of freedom For average use in from stenosis a a greater XX% reduction following first revascularization in And the
to the indication, the and the expanded to would make challenging plan completed, XXX(k) intravascular completion. through U.S, unique treat a to Once IDE include the is for we we imaging follow is an label in safely claim. the FDA pursue tremendous a on filing study difference proving ability which in Our excited ISR this with to the are Pantheris to application study
of sustainable leaner, our business. against in a the the with metric reported throughout more as we’ve expense committed of revenue continue we the become Finally, on a continued this remainder improve growth maintaining loss to previous in these in we we’ve and operating stronger and to all trend expenses. of operating very gross made operating organization this by We’ve with are years, the and revenue strategic and the significantly ramp XXXX, we’re beyond. initiatives spite to quarter, lower lowest of higher more focused growth resulted second quarter in the while than progress upsurge that holding this progress we focused and XXXX translating three In Combined activity. flat recurring margins made
to Mark results. At this point, I’d over turn call financial the discuss to
